Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration
SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech” or the “Company”) is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab (“PTB”) successfully blocked viral entry into cells. Based on these results, PTB and will be advanced to laboratory-based animal studies.
Alison Patteson, an assistant professor of physics, is leading a team researching the connections between the COVID-19 virus and pritumumab, a naturally occurring antibody, which has been used to inhibit cancer and tumor growth. Patteson tested whether the antibody blocks SARS-CoV-2, the virus responsible for COVID-19, from entering cells. “Evidence has been found that the antibody does block the uptake to viral particles,” Patteson said. The entire Syracuse Press release can be seen at: http://dailyorange.com/2020/10/professor-researches-antibody-possible-treatment-covid-19/
Nascent Senior Medical Consultant, Dr. Navpaul Singh M.D., stated, “the In Vitro results indicating that PTB can block uptake of COVID-19 is great as less viral load corresponds to less patient symptoms. These results may be suggestive of use in a combination therapy with drugs targeting other pathways. ”
An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus which was instrumental in Nascent’s investigation into Viral Infections.
Nascent’s Management is continuing development in Viral Infections along with opening the Phase I Brain Cancer Clinical Trial at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian.
About Nascent Biotech Inc
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CEO Nascent Biotech, Inc
6330 Nancy Ridge Dr
San Diego CA 92121
SOURCE: Nascent Biotech, Inc.